Jose Mesa

Jose Mesa is a seasoned venture capital investor and board member with extensive experience in the biotechnology sector. Here are key details about his background and current role:

Professional Experience

Jose Mesa has over 15 years of experience in venture investments in the biotechnology field.1 His career highlights include:

• Currently serving as a Board Director at ARTHEx Biotech24
• Partner at Columbus Venture Partners, a venture capital firm3
• Previously led the Life Sciences area at Caixa Capital Risc, managing over 100 million euros for biotech investments1
• Former partner at Alta Life Sciences, a Barcelona-based venture capital firm focused on biotechnology and medical technologies1

Education

Mesa holds several advanced degrees:

• MSc in Genetics from Universidad Complutense de Madrid (2001)1
• MSc in Corporate Finance from Universidad Autónoma of Madrid (2005)1
• MBA from IESE Business School (2003)1
• Executive Programme (PDD) from IESE Business School (2011)1

Role at ARTHEx Biotech

As a Board Director at ARTHEx Biotech, Mesa is involved in guiding the company's strategic decisions. ARTHEx Biotech is a clinical-stage biotechnology company focusing on developing innovative medicines through microRNA modulation.2

In May 2023, Mesa played a key role in ARTHEx Biotech's €42 million Series B financing round, which was led by Columbus Venture Partners.2 He expressed confidence in the company's approach to unlocking new therapeutic potential with microRNAs, particularly for the treatment of Myotonic Dystrophy Type 1 (DM1).2

Recent Developments

On February 28, 2024, Mesa shared on his LinkedIn profile (username: joseantoniomesa) that ARTHEx Biotech received FDA clearance to start its Phase I/IIa trial in Muscular Dystrophy Type 1, describing it as "Great news from our portfolio!"5

Jose Mesa's extensive experience in biotech investments and his current role at ARTHEx Biotech position him as a key figure in the development of innovative therapies for rare diseases.